A detailed history of Quent Capital, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Quent Capital, LLC holds 423 shares of VRTX stock, worth $196,728. This represents 0.02% of its overall portfolio holdings.

Number of Shares
423
Previous 399 6.02%
Holding current value
$196,728
Previous $166,000 19.28%
% of portfolio
0.02%
Previous 0.02%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 08, 2024

BUY
$392.81 - $485.53 $9,427 - $11,652
24 Added 6.02%
423 $198,000
Q1 2024

May 02, 2024

BUY
$407.69 - $446.08 $40,361 - $44,161
99 Added 33.0%
399 $166,000
Q4 2023

Jun 14, 2024

BUY
$343.0 - $410.68 $40,474 - $48,460
118 Added 64.84%
300 $122,000
Q4 2023

Jan 19, 2024

BUY
$343.0 - $410.68 $40,474 - $48,460
118 Added 64.84%
300 $122,000
Q3 2023

Jun 14, 2024

BUY
$338.18 - $362.46 $32,465 - $34,796
96 Added 111.63%
182 $63,000
Q3 2023

Oct 10, 2023

BUY
$338.18 - $362.46 $32,465 - $34,796
96 Added 111.63%
182 $63,000
Q2 2023

Jun 14, 2024

BUY
$314.42 - $351.91 $12,891 - $14,428
41 Added 91.11%
86 $30,000
Q2 2023

Jul 10, 2023

BUY
$314.42 - $351.91 $12,891 - $14,428
41 Added 91.11%
86 $30,000
Q1 2023

Jun 14, 2024

SELL
$283.23 - $323.1 $100,263 - $114,377
-354 Reduced 88.72%
45 $14,000
Q1 2023

Apr 05, 2023

SELL
$283.23 - $323.1 $4,531 - $5,169
-16 Reduced 26.23%
45 $14,000
Q4 2022

Jan 19, 2023

BUY
$285.76 - $321.48 $3,429 - $3,857
12 Added 24.49%
61 $0
Q3 2022

Nov 10, 2022

BUY
$273.83 - $305.53 $1,369 - $1,527
5 Added 11.36%
49 $14,000
Q2 2022

Aug 08, 2022

BUY
$234.96 - $292.55 $1,879 - $2,340
8 Added 22.22%
44 $12,000
Q1 2022

May 12, 2022

SELL
$221.42 - $260.97 $12,399 - $14,614
-56 Reduced 60.87%
36 $9,000
Q4 2021

May 12, 2022

BUY
$177.01 - $223.45 $2,832 - $3,575
16 Added 21.05%
92 $20,000
Q4 2021

Feb 28, 2022

BUY
$177.01 - $223.45 $13,452 - $16,982
76 New
76 $17,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Quent Capital, LLC Portfolio

Follow Quent Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quent Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quent Capital, LLC with notifications on news.